SDHB is altered in 0.97% of clear cell renal cell carcinoma patients with SDHB Frameshift present in 0.14% of all clear cell renal cell carcinoma patients [4].

SDHB Frameshift is an inclusion criterion in 1 clinical trial for clear cell renal cell carcinoma, of which 0 are open and 1 is closed. Of the trial that contains SDHB Frameshift and clear cell renal cell carcinoma as inclusion criteria, 1 is phase 1 (0 open) [5].

SDHB is altered in 0.53% of renal cell carcinoma patients with SDHB Frameshift present in 0.08% of all renal cell carcinoma patients [4].

SDHB Frameshift is an inclusion criterion in 1 clinical trial for renal cell carcinoma, of which 0 are open and 1 is closed. Of the trial that contains SDHB Frameshift and renal cell carcinoma as inclusion criteria, 1 is phase 1 (0 open) [5].

SDHB is altered in 0.46% of breast carcinoma patients with SDHB Frameshift present in 0.03% of all breast carcinoma patients [4].

SDHB Frameshift is an inclusion criterion in 1 clinical trial for breast carcinoma, of which 0 are open and 1 is closed. Of the trial that contains SDHB Frameshift and breast carcinoma as inclusion criteria, 1 is phase 1 (0 open) [5].

SDHB is altered in 0.56% of malignant solid tumor patients with SDHB Frameshift present in 0.01% of all malignant solid tumor patients [4].

SDHB Frameshift is an inclusion criterion in 1 clinical trial for malignant solid tumor, of which 0 are open and 1 is closed. Of the trial that contains SDHB Frameshift and malignant solid tumor as inclusion criteria, 1 is phase 1 (0 open) [5].

SDHB is altered in 1.15% of gastrointestinal stromal tumor patients [4].

SDHB Frameshift is an inclusion criterion in 1 clinical trial for gastrointestinal stromal tumor, of which 0 are open and 1 is closed. Of the trial that contains SDHB Frameshift and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1 (0 open) [5].

SDHB is altered in 0.48% of non-small cell lung carcinoma patients [4].

SDHB Frameshift is an inclusion criterion in 1 clinical trial for non-small cell lung carcinoma, of which 0 are open and 1 is closed. Of the trial that contains SDHB Frameshift and non-small cell lung carcinoma as inclusion criteria, 1 is phase 1 (0 open) [5].

SDHB Frameshift is an inclusion criterion in 1 clinical trial for papillary renal cell carcinoma, of which 0 are open and 1 is closed. Of the trial that contains SDHB Frameshift and papillary renal cell carcinoma as inclusion criteria, 1 is phase 1 (0 open) [5].

SDHB Frameshift is an inclusion criterion in 1 clinical trial for peritoneal mesothelioma, of which 0 are open and 1 is closed. Of the trial that contains SDHB Frameshift and peritoneal mesothelioma as inclusion criteria, 1 is phase 1 (0 open) [5].

SDHB is altered in 0.21% of pleural mesothelioma patients [4].

SDHB Frameshift is an inclusion criterion in 1 clinical trial for pleural mesothelioma, of which 0 are open and 1 is closed. Of the trial that contains SDHB Frameshift and pleural mesothelioma as inclusion criteria, 1 is phase 1 (0 open) [5].